Company: PIII
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001140361-25-016302
Chunk: 29

Company: P3 Health Partners Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 29
---
 the Company and, thereafter, by our entire Board. After further careful consideration, including of our current cash position and continuing liquidity needs, our Board determined to recommend that our stockholders approve the issuance of Class A common stock upon the exercise of the VBC 4 Warrants. Although there can be no assurance that VBC 4 will exercise all, or any part of, the VBC 4 Warrants, at an exercise price of $10.34 per share of Class A common stock (as adjusted for the Reverse Stock Split), the full exercise of such VBC 4 Warrants would result in gross proceeds to the Company of approximately $14.7 million. In connection with any exercise of VBC 4 Warrants, we currently intend to use the proceeds from such exercises for working capital and general corporate purposes. Interests of Certain Persons When you consider our Board’s recommendation to vote in favor of this proposal, you should be aware that VBC 4 is an affiliate of Chicago Pacific Founders, our principal stockholder, and, as a result, certain of our directors and our principal stockholder may have interests that may be different from, or in addition to, the interests of other of our stockholders. For additional information, see “Certain Relationships and Related Person Transactions” below. Vote Required This proposal requires the approval of the affirmative vote of the majority of the votes cast. Abstentions and broker non-votes will have no effect on this proposal. Recommendation of the Board of Directors

| The Board of Directors unanimously recommends a vote FOR the approval, in accordance with Nasdaq Listing Rule 5635(d), of the issuance of up to 1,428,129 shares of Class A common stock upon the exercise of outstanding Class A common stock warrants held by VBC Growth SPV 4, LLC. |

17

TABLE OF CONTENTS

EXECUTIVE OFFICERS The following table sets forth certain information with respect to our current executive officers as of the date of this proxy statement.

| Name                  |     | Age |     | Position                                       |
| Aric Coffman, M.D.(1) |     |  52 |     | Chief Executive Officer and President          |
| Amir Bacchus, M.D.(2) |     |  61 |     | Chief Medical Officer, Director and Co-Founder |
| Leif Pedersen(3)      |     |  49 |     | Chief Financial Officer                        |

| (1) | Aric Coffman was appointed as